Skip to main content
    B

    Beta Bionics, Inc. Common Stock (BBNX)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $14.72
    -0.49 (-3.22%)

    Market Cap: $826.92M

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Beta Bionics, Inc. Common Stock (BBNX) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Beta Bionics, Inc. Common Stock (BBNX) has a market cap of $826.92M and an enterprise value of $750.02M. It kept -65.31% of revenue as net income over the last 12 months. Revenue grew 43.69% over the last 12 months from the 12 months before.

    Total Valuation

    Enterprise value is 9.30% below the market cap, as cash exceeds debt.

    Market Cap$826.92M
    Enterprise Value$750.02M
    Latest price (Nov 17, 2026)$14.72

    Key Dates

    The next earnings report is expected on Feb 15, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 15, 2027 (expected)
    Last Earnings DateOct 27, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 4.48% in the quarter ended Sep 30, 2026 and grew 3.62% a year over 2 years.

    Shares Outstanding46.54M
    Shares Change (YoY)+6.66%
    Shares Change (QoQ)+4.48%
    Share Count Growth (2Y CAGR)+3.62%

    Valuation Ratios

    Sales and book value multiples are 5.4x and 1.7x.

    P/S Ratio5.4x
    Forward P/S6.6x
    P/B Ratio1.7x

    Price Statistics

    The stock is down 45.84% over 52 weeks and trades 19.52% below its 50-day average.

    Beta (1Y)1.51
    52-Week Change-45.84%
    1-Month Change-12.59%
    3-Month Change-26.44%
    6-Month Change+56.26%
    Total Return (1Y)-45.84%
    Return vs SPY (1Y)-57.26%
    Max Drawdown (1Y)-72.30%
    Sharpe Ratio (1Y)-0.69
    Correlation with SPY (1Y)0.23
    50-Day Average$18.29
    200-Day Average$14.83
    52-Week Range$8.80 to $32.71
    RSI (14 Days)39.5
    Average Volume (20 Days)1.17M

    Financial Position

    Current assets cover 8.92x current liabilities, and total debt is 0.01x shareholder equity.

    Current Ratio8.92x
    Quick Ratio8.22x
    Debt / Equity0.01x

    Returns and Efficiency

    Return on invested capital is -18.01% and return on equity is -20.71% over the last 12 months.

    Return on Equity (ROE)-20.71%
    Return on Assets (ROA)-18.73%
    Return on Invested Capital (ROIC)-18.01%
    Asset Turnover0.33x
    Inventory Turnover2.25x
    Receivables Turnover6.57x
    Cash Conversion Cycle183 days

    Scores

    BBNX has an Altman Z-Score of 8.62, in the safe zone above 2.99, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.

    Altman Z-Score8.62
    Altman Z ZoneSafe
    Piotroski F-Score4 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was $127.27M over the last 12 months.

    Revenue$127.27M
    Revenue Growth (YoY)+43.69%
    Gross Profit$74.61M
    Operating Income-$92.58M
    Pretax Income-$83.11M
    Net Income-$83.12M
    Reported EPS (TTM)-$1.71

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 90.45% of the $443.76M in total assets.

    Cash and Equivalents$81.55M
    Total Debt$4.65M
    Net Cash$76.90M
    Net Cash Per Share$1.65
    Working Capital$260.11M
    Shareholder Equity$401.38M
    Book Value Per Share$8.62
    Total Assets$443.76M
    Total Liabilities$42.38M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $6.59M of capital spending, operating cash flow left -$65.96M of free cash flow.

    Operating Cash Flow-$59.37M
    Capital Expenditures$6.59M
    Free Cash Flow-$65.96M
    FCF Per Share-$1.22
    Depreciation and Amortization$4.64M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -72.75%.

    Gross Margin58.63%
    Operating Margin-72.75%
    Pretax Margin-65.31%
    Net Margin-65.31%
    FCF Margin-51.83%

    Dividends and Yields

    BBNX does not pay a dividend. Its free cash flow yield is -9.63%.

    FCF Yield-9.63%
    Buyback Yield-24.10%
    Shareholder Yield-24.10%

    Peer Position

    Against 12 similar companies, BBNX has the 4th highest P/S.

    P/S Ratio5.4x vs 3.3x median
    ROIC-18.01% vs -6.00% median
    Revenue Growth (Trailing 4 Quarters, YoY)+43.69% vs +14.00% median

    Competitors compared

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About BBNX

    What is BBNX's market cap?

    Beta Bionics, Inc. Common Stock has a market cap of $826.92M. Its enterprise value, which adds debt and subtracts cash, is $750.02M.

    How many shares of BBNX are outstanding?

    Beta Bionics, Inc. Common Stock has 46.54M shares outstanding. The count is up 6.66% from a year earlier.

    Does BBNX pay a dividend?

    No. Beta Bionics, Inc. Common Stock does not pay a dividend.

    How much debt does BBNX have?

    Beta Bionics, Inc. Common Stock has $4.65M of total debt and $81.55M of cash and equivalents, a net cash position of $76.90M.